Commentary|Articles|August 25, 2026

Behind the FDA Approval: ‘Historic’ Iberdomide Trial Spotlights MRD End Point and Potential of CELMoDs Across Myeloma

Author(s)Surbhi Sidana, MD, Jonah Feldman

In an interview, Surbhi Sidana, MD, explores the significance of iberdomide's FDA approval and how this agent fits into the growing array of novel multiple myeloma therapies.

The recent FDA approval of iberdomide (Zenbexus) represents more than the approval of a single new drug for relapsed/refractory multiple myeloma and heralds a major shakeup for the treatment of the disease beyond any single trial. The first approved cereblon E3 ligase modulator (CELMoD) presents the opportunity to improve upon the foundation laid by immunomodulatory drugs (IMiDs) in multiple myeloma and fits seamlessly into the growing armamentarium available for relapsed disease.